Introduction: Colorectal cancer (CRC) is a major health problem Worldwide, Egypt shows a high rate of early CRC in the world as 35% of 1,600 Egyptian CRC patients were under 40 with threefold increased risk of death within 5 years. DNA methylation-based biomarkers as methylated Septin9 (mSEPT9) has a promising role for detecting CRC. As well as set of nuclear matrix proteins associated with changes in the nuclear structure/architecture. detection of these nuclear proteins resulted in identification of biomarkers that are specific for colon cancer. Particular interest has been placed on colon cancer specific antigen-2(CCSA-2). Methods: A total of 30 newly diagnosed CRC patients, 7 colonic adenoma patients, and 15 age- and sex-matched control subjects were recruited in this study. Plasma mSEPT9was assayed by Epi procolon kit, CCSA-2 by ELISA and, Occult blood in stool by Guaiac-based fecal occult blood test. The level of Colon Cancer mSEPT9 and CCSA-2 were carried on CRC patients both preoperatively and three months postoperatively. Results: mSEPT9 has 96.7% sensitivity and 95.5% specificity in differentiating colorectal cancer patients from non-malignant cases. Also, our study showed a highly statistically significant difference between the pre and three months postoperative expression of mSEPT9 in colorectal cancer as there was a dramatically decrease in the expression of mSEPT9 postoperatively (p value < 0.001). The CCSA-2 at the cutoff level of >1.43 would provide 93.3% sensitivity and 90.9% specificity in differentiation between malignant and non-malignant cases. Also, the study showed that there is a statistically significant difference between colorectal cancer patients preoperatively and postoperatively according to CCSA-2 with dramatic decrease in its level postoperatively (p value > 0.001). Conclusion: The plasma SEPT9 DNA methylation level and Serum CCSA-2 could be used as promising non-invasive methods for observing the CRC patients postsurgical response to predict the occurrence of complete remission or relapses.
Abd El Kader, L., Soliman, A., Salem, S., Akel, S., & Ibrahim, N. (2023). The Clinical Significance of Septin 9 and Colon Cancer Specific Antigen-2 (CCSA-2) in Colorectal Cancer. Asian Pacific Journal of Cancer Prevention, 24(3), 1027-1036. doi: 10.31557/APJCP.2023.24.3.1027
MLA
Lamiaa Abd El Kader; Amira H Soliman; Salem E Salem; Samia Y Akel; Noha H Ibrahim. "The Clinical Significance of Septin 9 and Colon Cancer Specific Antigen-2 (CCSA-2) in Colorectal Cancer". Asian Pacific Journal of Cancer Prevention, 24, 3, 2023, 1027-1036. doi: 10.31557/APJCP.2023.24.3.1027
HARVARD
Abd El Kader, L., Soliman, A., Salem, S., Akel, S., Ibrahim, N. (2023). 'The Clinical Significance of Septin 9 and Colon Cancer Specific Antigen-2 (CCSA-2) in Colorectal Cancer', Asian Pacific Journal of Cancer Prevention, 24(3), pp. 1027-1036. doi: 10.31557/APJCP.2023.24.3.1027
VANCOUVER
Abd El Kader, L., Soliman, A., Salem, S., Akel, S., Ibrahim, N. The Clinical Significance of Septin 9 and Colon Cancer Specific Antigen-2 (CCSA-2) in Colorectal Cancer. Asian Pacific Journal of Cancer Prevention, 2023; 24(3): 1027-1036. doi: 10.31557/APJCP.2023.24.3.1027
)